Journal of Clinical Oncology
Articles in this Issue
Class-specific clinical and molecular features of <i>SMARCA4</i> alterations in non–small cell lung cancer.
8033 Background: SMARCA4 mutations occur in 5–10% of non-small cell lung cancers (NSCLCs) and are asso...
Efficacy of adjuvant anti–PD-1/anti–PD-L1 immunotherapy in resected renal cell carcinoma (RCC): An updated systematic review and meta-analysis.
e16508 Background: To systematically review and meta-analyze randomized controlled trials (RCTs) evaluating adjuvant immun...
Ivermectin use in patients with cancer over the past decade at an academic cancer center.
e23175 Background: Patient interest in ivermectin has increased over time, initially as potential treatment for COVID-19 a...
Plastic and single-use materials in breast cancer screening and diagnosis: A multi-center audit of modifiable resource use in oncology care.
e23159 Background: Breast cancer screening and diagnostic pathways are central to modern oncology care and rely on imaging...
Culmerciclib (CDK2/4/6 inhibitor) plus fulvestrant in HR+/HER2− advanced breast cancer after progression on CDK4/6i: Preliminary results from a phase II trial.
1082 Background: CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) have been the standard first line...
Clinicopathological characteristics and survival outcomes of typical and atypical pulmonary carcinoid tumors: A 13-year single-center retrospective study.
e20090 Background: Pulmonary neuroendocrine neoplasms (NENs) range from low-grade typical and atypical carcinoids to high-...
FusionVAC22_02, a phase I clinical trial in progress: Adjuvant <i>DNAJB1-PRKACA</i> fusion transcript–based peptide T-cell activator for fibrolamellar hepatocellular carcinoma (FLC) and other tumor entities carrying the oncogenic driver fusion.
TPS4270 Background: The DNAJB1-PRKACA fusion transcript was detected as the oncogenic driver of tumor pathogenesis in fibr...
Nivolumab plus ipilimumab combined with chemotherapy as first-line treatment for HER2-negative unresectable advanced or recurrent gastric/gastroesophageal junction cancer: A randomized phase 3 trial (ATTRACTION-6).
4006 Background: Anti-PD-1 antibodies combined with chemotherapy (Chemo) are established as a standard first-line (1L) tre...
Sociodemographic predictors of palliative care utilization across a mid-Atlantic healthcare system.
e13736 Background: Patients with advanced (Stage III, IV) cancer have high symptom burden that significantly impacts patie...
Concordance of liquid biopsy and tissue CGP for identification of guideline-recommended actionable variants.
e15061 Background: Comprehensive genomic profiling (CGP) is essential for managing patients (pts) with advanced solid tumo...
Inpatient chemotherapy in small cell lung cancer as a high-risk care-delivery phenotype: National Inpatient Sample analysis.
e23193 Background: Small cell lung cancer (SCLC) is typically treated with outpatient systemic therapy; inpatient chemothe...
The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on outcomes in metastatic non-small cell lung cancer (mNSCLC) patients treated with tyrosine kinase inhibitors (TKIs): Real-world retrospective analysis.
8636 Background: The therapeutic landscape of mNSCLC has rapidly evolved, with multiple oncogenic alterations now targetab...
Zongertinib combination therapy in HER2-positive metastatic breast cancer (mBC): First results from a phase Ib/II trial.
1044 Background: Zongertinib, an irreversible TKI, selectively inhibits HER2 while sparing wild-type EGFR, thereby minimiz...
Life-course epidemiology of body size and risk of early and advanced breast cancer.
e22627 Background: There has been limited studies of the life-course epidemiology of body sizes and the risk of early and...
Prognostic and predictive value of baseline derived neutrophil-to-lymphocyte ratio (dNLR) in <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC) receiving 5-fluorouracil and folinic acid (FU/FA) with or without panitumumab (Pmab) maintenance: A post-hoc analysis of the PANAMA/AIO KRK 0212) trial.
e15552 Background: The derived neutrophil-to-lymphocyte ratio (dNLR) is an established prognostic marker in solid tumors i...
Reproducible modulation of tissue Ki-67 across lung and prostate cancer interception trials.
10574 Background: The clinical utility of cancer interception is limited by the lack of validated surrogate endpoints that...
Tumor load change as a functional biomarker for prognosis and treatment modulation in metastatic colorectal cancer (mCRC): Individual patient data (IPD) analysis of 12 randomized trials.
3561 Background: The use of overall response rate (ORR) and progression-free survival (PFS) as surrogacy of overall surviv...
Second primary malignancies in patients with chronic lymphocytic leukemia: A SEER analysis, 2000–2022.
e18587 Background: Survivors of chronic lymphocytic leukemia (CLL) face an increased risk of second primary malignancies (...
Histology and stage-specific incidence trends in appendiceal adenocarcinoma in the United States, 2000–2022: A SEER analysis.
e15701 Background: Appendiceal adenocarcinoma is rare, but recent population-based studies suggest a rising incidence. We...
LITESPARK-033: Phase 3 study of belzutifan plus zanzalintinib versus cabozantinib for recurrent clear cell renal cell carcinoma during or after adjuvant anti–PD-(L)1 therapy.
TPS4633 Background: Adjuvant pembrolizumab is standard of care for patients with renal cell carcinoma (RCC) at increased r...
Designing a solid tumor oncology curriculum for medical residents: A single-institution needs assessment.
e21011 Background: Patients with solid tumor malignancies comprise a large portion of inpatient medicine admissions at man...
Testing, treatment, and teamwork: Differential learning curves and translational barriers in EGFR-mutated NSCLC care.
e23216 Background: Advances in EGFR-targeted therapies have transformed the management of non–small cell lung cancer (NSCL...
Racial differences in clinical, genomic, and survival outcomes in colorectal cancer.
10593 Background: Racial differences influence colorectal cancer incidence, biology, and survival, but the clinical and ge...
Exploration of tumor-informed ctDNA detection and dynamics in a real-world cohort of colorectal cancer patients from the MD Anderson Cancer Center.
e15658 Background: Circulating tumor DNA (ctDNA) is a promising tool for the treatment of patients with cancer. In the col...
AcTION: Phase 1 study of [ <sup>225</sup> Ac]Ac-PSMA-617 ( <sup>225</sup> Ac-PSMA-617) in men with metastatic castration-resistant prostate cancer (mCRPC) with or without prior [ <sup>177</sup> Lu]Lu-PSMA ( <sup>177</sup> Lu-PSMA) radioligand therapy (RLT).
5010 Background: AcTION is the first prospective dosage escalation study of 225 Ac...